These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26944649)

  • 21. Glatiramer acetate in the treatment of multiple sclerosis.
    Miller AE
    Neurol Clin; 2005 Feb; 23(1):215-31, viii. PubMed ID: 15661095
    [No Abstract]   [Full Text] [Related]  

  • 22. [Disease modifying drugs in multiple sclerosis and pregnancy].
    Tur C; Tintoré M; Aguilera C
    Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
    [No Abstract]   [Full Text] [Related]  

  • 23. Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis.
    Schipper HM; Arnold D; GrandʼMaison F; Melmed C; Moore F; Levental M; Su H; Constantin M; Stril JL; Godin J
    Clin Neuropharmacol; 2015; 38(4):127-31. PubMed ID: 26166235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ulnar neuropathy after glatiramer acetate subcutaneous injection: Ultrasound findings.
    Coraci D; Giovannini S; Loreti C; Padua L
    J Clin Pharm Ther; 2019 Feb; 44(1):140-141. PubMed ID: 30315577
    [No Abstract]   [Full Text] [Related]  

  • 25. Glatiramer acetate: successful desensitization for treatment of multiple sclerosis.
    Bains SN; Hsieh FH; Rensel MR; Radojicic C; Katz HT; Inamdar SR; Lang DM
    Ann Allergy Asthma Immunol; 2010 Apr; 104(4):321-5. PubMed ID: 20408342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for use of glatiramer acetate in multiple sclerosis.
    Caramanos Z; Arnold DL
    Lancet Neurol; 2005 Feb; 4(2):74-5; discussion 76-7. PubMed ID: 15664538
    [No Abstract]   [Full Text] [Related]  

  • 27. Evidence for use of glatiramer acetate in multiple sclerosis.
    Comi G; Hartung HP; Martinelli Boneschi F
    Lancet Neurol; 2005 Feb; 4(2):75-6; discussion 76-7. PubMed ID: 15664539
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.
    Ehling R; Di Pauli F; Lackner P; Rainer C; Kraus V; Hegen H; Lutterotti A; Kuenz B; De Zordo T; Schocke M; Glatzl S; Löscher WN; Deisenhammer F; Reindl M; Berger T
    J Neuroimmunol; 2015 Oct; 287():98-105. PubMed ID: 26439969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation.
    Fragoso YD
    Expert Opin Drug Saf; 2014 Dec; 13(12):1743-8. PubMed ID: 25176273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple sclerosis: the role of melatonin and N-acetylserotonin.
    Anderson G; Rodriguez M
    Mult Scler Relat Disord; 2015 Mar; 4(2):112-23. PubMed ID: 25787187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.
    Moreau T
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S12-5. PubMed ID: 19200858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful Rapid Desensitization to Glatiramer Acetate in a Patient With Multiple Sclerosis.
    Syrigou E; Psarros P; Grapsa D; Syrigos K
    J Investig Allergol Clin Immunol; 2015; 25(3):214-5. PubMed ID: 26182688
    [No Abstract]   [Full Text] [Related]  

  • 34. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.
    Cohen BA; Coyle PK; Leist T; Oleen-Burkey MA; Schwartz M; Zwibel H
    Mult Scler Relat Disord; 2015 Jan; 4(1):75-82. PubMed ID: 25787057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aseptic meningitis after glatiramer acetate.
    Niessen A; Schwarz B; Urban M; Krämer S; Reinhard M
    J Neurol; 2021 Jul; 268(7):2589-2590. PubMed ID: 33909159
    [No Abstract]   [Full Text] [Related]  

  • 36. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
    Pöllmann W; Erasmus LP; Feneberg W; Straube A
    Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of delayed diagnosis and treatment in clinically isolated syndrome and multiple sclerosis.
    Kennedy P
    J Neurosci Nurs; 2013 Dec; 45(6 Suppl 1):S3-13. PubMed ID: 24217189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action.
    Farina C; Weber MS; Meinl E; Wekerle H; Hohlfeld R
    Lancet Neurol; 2005 Sep; 4(9):567-75. PubMed ID: 16109363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacological treatment of multiple sclerosis].
    Myhr KM
    Tidsskr Nor Laegeforen; 2010 Mar; 130(5):490-2. PubMed ID: 20224616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.